Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| aTYR PHARMA INCATYR · Entity 7233 | Chief Financial Officer | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
aTYR PHARMA INC
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2036-10-01 | Direct | 410,000 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 410,000 · Balance 410,000 F1: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning November 1, 2026, such that this option will be fully exercisable on November 1, 2030. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning November 1, 2026, such that this option will be fully exercisable on November 1, 2030. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 00:03 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 410,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0002156611-26-000010 · ownership.xml · derivative · entry 1 Yaras Brandon · CIK 0002156611 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2036-10-01 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning November 1, 2026, such that this option will be fully exercisable on November 1, 2030. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.